Sunitinib: A novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)

Therapeutics and Clinical Risk Management

Volumn 3, Issue 2, 2007, Pages 341-348

  Le Tourneau, Christophe ^a   Raymond, Eric ^a   Faivre, Sandrine ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

GIST; Renal cell carcinoma; Review; Sunitinib; Targeted therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; ERLOTINIB; FLT3 LIGAND; IMATINIB; INTERLEUKIN 2; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADRENAL DISEASE; ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW DEPRESSION; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 34250020187     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.2.341     Document Type: Review

References (51)

1. Abrams TJ, Lee JB, Murray LJ, et al. 2003. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther, 2:471-8.
2. Abrams TJ, Murray LJ, Pesenti E, et al. 2003. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther, 2:1011-21.
3. Ahmad T, Eisen T. 2004. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res, 10(18 Pt 2):6388S-92S.
4. Baratte S, Sarati S, Frigerio E, et al. 2004. Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A, 1024(1-2):87-94.
5. Bardos JL, Aschcroft M. 2004. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays, 26:262-9.
6. Bergers G, Song S, Meyer-Morse N, et al. 2003. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest, 111:1287-95.
7. Blanke CD, Corless CL. 2005. State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest, 23:274-80.
8. Corless CL, Fletcher JA, Heinrich MC. 2004. Biology of gastrointestinal stromal tumors. J Clin Oncol, 22:3813-25.
9. De Mulder PH, Roigas J, Gillessen S, et al. 2006. A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine refractory metastatic renal cell carcinoma (mRCC). American Society of Clinical Oncology 42th Annual Meeting,2-6 June. Atlanta, USA.
10. Demetri GD, von Mehren M, Blanke CD, et al. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347:472-80.
11. Demetri DG, van Oosterom A, Blackstein M, et al. 2005. Phase 3 multicenter, randomized, double-bind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. American Society of Clinical Oncology 41st Annual Meeting, 13-17 May, Orlando, Florida, USA.
12. Deprimo SE, Bello CL, Smeraglia J, et al. 2005. Soluble protein biomarkers of pharmacodynamic activity of the multitargeted tyrosine kinase inhibitor SU11248 in patients with metastatic renal cell carcinoma. 96th Annual Meeting of the American Association for Cancer Research, 16-21 April, Anaheim, California, USA.
13. Escudier B, Szczylik C, Eisen T, et al. 2005. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). American Society of Clinical Oncology 41st Annual Meeting, 13-17 May, Orlando, Florida, USA.
14. Fabian MA, Biggs WH, Treiber DK, et al. 2005. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol, 23:329-36.
15. Faivre S, Delbaldo C, Vera K, et al. 2006. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol, 24:25-35.
16. Ferrara N, Hillan KJ, Gerber HP, et al. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3:391-400.
17. George S, Casali PG, Blay J, et al. 2006. Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST. American Society of Clinical Oncology 42th Annual Meeting, 2-6 June, Atlanta, USA.
18. Hainsworth JD, Sosman JA, Spigel DR, et al. 2005. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol, 23:7889-96.
19. Heinrich MC, Corless MC, Demetri GD, et al. 2003. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol, 21:4342-9.
20. Hudes G, Carducci M, Tomczak P, et al. 2006. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR+IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). American Society of Clinical Oncology 42th Annual Meeting, 2-6 June. Atlanta, USA.
21. Hurwitz H, Fehrenbacher L, Novotny W, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350:2335-42.
22. Kamura T, Sato S, Iwai K, et al. 2000. Activation of HIF1 alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA, 97:10430-5.
23. Kerbel R, Folkman J. 2002. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 2:727-39.
24. Kulke M, Lens HJ, Meropol NJ, et al. 2005. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). American Society of Clinical Oncology 41st Annual Meeting, 13-17 May, Orlando, Florida, USA.
25. Lam JS, Leppert JT, Belldegrun AS, et al. 2005. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol, 23:202-12.
26. Latif F, Tory K, Gnarra J, et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science, 260:1317-20.
27. Lenz H, Marshall J, Rosen L, et al. 2006. Phase II trial of SU11248 in patients with metastatic colorectal cancer (MCRC) after failure of standard chemotherapy. American Society of Clinical Oncology Gastrointestinal 4th Annual Meeting, 27-29 January, San Fransisco, USA.
28. Maki RG, Fletcher JA, Heinrich MC, et al. 2005. SU11248 in patients with imatinib-resistant GIST : results from a continuation trial. American Society of Clinical Oncology 41st Annual Meeting, 13-17 May, Orlando, Florida, USA.
29. Mendel DB, Laird AD, Xin X, et al. 2003. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res, 9:327-37.
30. Miller KD, Burstein HJ, Elias AD, et al. 2005. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium 28th Annual Meeting, 8-11 December, San Antonio, Texas, USA.
31. Morimoto AM, Tan N, West K, et al. 2004. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene, 23:1618-26.
32. Motzer RJ, Bander NH, Nanus DM, et al. 1996. Renal-cell carcinoma. N Engl J Med, 335:865-75.
33. Motzer RJ, Bacik J, Schwartz LH, et al. 2004. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol, 22:454-63.
34. Motzer RJ, Rini BI, Bukowski RM, et al. 2006. Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 295:2516-24.
35. Motzer RJ, Michaelson MD, Redman BG, et al. 2006. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24:16-24.
36. Motzer RJ, Hutson TE, Tomczak MD, et al. 2006. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). American Society of Clinical Oncology 42st Annual Meeting, 2-6 June, Atlanta, USA.
37. Murray LJ, Abrams TJ, Long KR, et al. 2003. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis, 20:757-66.
38. O'Farrell AM, Foran JM, Fiedler W, et al. 2003. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res, 9:5465-76.
39. Patel PH, Chaganti RSK, Motzer RJ. 2006. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer, 94:614-19.
40. Ratain MJ, Eisen T, Stadler WM, et al. 2005. Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). American Society of Clinical Oncology 41st Annual Meeting, 13-17 May, Orlando, Florida, USA.
41. Rohrmann K, Staehler M, Haseke N, et al. 2005. Immunotherapy in metastatic renal cell carcinoma. World J Urol, 23:196-201.
42. Ronnen EA, Kondagunta GV, Lau C, et al. 2006. A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC). American Society of Clinical Oncology 42th Annual Meeting, 2-6 June, Atlanta, USA.
43. Shaheen RM, Tseng WW, Davis DW, et al. 2001. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res, 61:1464-8.
44. Socinski MA, Novello S, Sanchez JM, et al. 2006. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. American Society of Clinical Oncology 42th Annual Meeting, 2-6 June, Atlanta, USA.
45. Toner GC, Mitchell PL, De Boer R, et al. 2003. PET imaging study of SU11248 in patients with advanced malignancies. American Society of Clinical Oncology 39th Annual Meeting, 31 May-3 June, USA.
46. Van Glabbeke M, Verweij J, Casali PG, et al. 2005. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol, 23:5795-804.
47. Verweij J, Casali PG, Zalcberg J, et al. 2004. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. Lancet, 364:1127-34.
48. Wang GL, Semenza GL. 1993. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A, 90:4304-8.
49. Willett CG, Boucher Y, di Tomaso E, et al. 2004. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10:145-7.
50. Yang JC, Haworth L, Sherry RM, et al. 2003. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 349:427-34.
51. Yee KW, Schittenheim M, O'Farrell AM, et al. 2004. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood, 104:4202-9.